ARTICLE | Distillery Therapeutics
Therapeutics: Interleukin-33 (IL-33; NF-HEV); monocyte chemoattractant protein-1 (MCP-1; CCL2)
March 5, 2015 8:00 AM UTC
In vitro and mouse studies suggest IL-33 agonists or CCL2 could treat SCI and other CNS injuries. In mouse models of SCI or optic nerve injury, IL-33 knockout decreased neuronal cell survival compared...